Table 1

Demographics and baseline characteristics at randomization

Placebo add-on to dapagliflozin plus metformin (n = 162)Saxagliptin add-on to dapagliflozin plus metformin (n = 153)Total population (N = 315)
Age, years54.5 ± 9.354.7 ± 9.854.6 ± 9.6
Women86 (53.1)80 (52.3)166 (52.7)
Race
 White141 (87.0)136 (88.9)277 (87.9)
 Black9 (5.6)11 (7.2)20 (6.3)
 Asian8 (4.9)5 (3.3)13 (4.1)
 Other4 (2.5)1 (0.7)5 (1.6)
BMI, kg/m231.4 ± 5.331.4 ± 5.231.4 ± 5.3
Duration of diabetes, years7.4 ± 5.88.1 ± 7.07.7 ± 6.4
HbA1c, % (mmol/mol)7.86 ± 0.93 (62 ± 10.2)7.97 ± 0.83 (64 ± 9.1)7.91 ± 0.88 (63 ± 9.6)
HbA1c category
 <8% (64 mmol/mol)99 (61.1)85 (55.6)184 (58.4)
 8–<9% (64–<75 mmol/mol)42 (25.9)50 (32.7)92 (29.2)
 ≥9% (75 mmol/mol)21 (13.0)18 (11.8)39 (12.4)
FPG, mg/dL158 ± 34.6164 ± 34.4161 ± 34.6
2-h PPG, mg/dL206 ± 53.1209 ± 50.1207 ± 51.6
Fasting C-peptide, ng/mL2.6 ± 1.22.4 ± 1.02.5 ± 1.1
eGFR, mL/min/1.73 m293.9 ± 20.692.8 ± 21.693.4 ± 21.1
  • Data are mean ± SD or n (%). eGFR, estimated glomerular filtration rate (calculated by the Modification of Diet in Renal Disease formula).